

**UNITED STATES SECURITIES AND EXCHANGE  
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

**OMB APPROVAL**

OMB Number: 3235-0104  
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>PFIZER INC</u>  (Last) (First) (Middle) <u>235 E 42ND ST</u>  (Street) <u>NEW YORK NY 10017</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/15/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>BioAtla, Inc. [ BCAB ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Series D Convertible Preferred Stock</u>	(1)	(1)	<u>Common Stock</u>	<u>2,238,090</u>	(1)	I	<u>See Footnote 2<sup>(2)</sup></u>

1. Name and Address of Reporting Person* <u>PFIZER INC</u>  (Last) (First) (Middle) <u>235 E 42ND ST</u>  (Street) <u>NEW YORK NY 10017</u>  (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Pfizer Ventures (US) LLC</u>  (Last) (First) (Middle) <u>235 EAST 42ND STREET</u>  (Street) <u>NEW YORK NY 10017</u>  (City) (State) (Zip)

**Explanation of Responses:**

1. Each share of Series D Convertible Preferred Stock will automatically convert into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. These share numbers reflect the 1-for-13 reverse split of the Common Stock effected by the Issuer on December 2, 2020. The Series D Convertible Preferred Stock has no expiration date.

2. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc.

Pfizer Inc. By: /s/Susan 12/15/2020

Grant, Assistant Secretary.

Pfizer Ventures (US) LLC

By: /s/Susan Grant, 12/15/2020

Secretary.

\*\* Signature of Reporting  
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**